Molecular Piracy Turns Protein Into Traitor

September 05, 1997

New Chemokine Holds Hope For HIV Treatment

An act of molecular piracy may put Glaxo Wellcome scientists on the track of drugs that would prevent HIV from entering human cells. Human herpes virus 8 (HHV-8) appears to have stolen a gene from the human host which codes for a chemokine. The virus then transformed it into a potent and broad-spectrum blocker of our chemokine system. Recent research has shown that two of the chemokine receptors blocked by the new molecule, CCR5 and CXCR4, are co-receptors essential for HIV infection of human cells.

This is the first naturally occurring chemokine antagonist. In humans, chemokines, also called chemoattractant cytokines, regulate the movement of white blood cells. However, in this case, the virus has modified the original human chemokine so that it binds to the chemokine receptor but does not stimulate the normal response. Instead, the resulting viral chemokine, vMIP-II, acts as an antagonist blocking the normal action of the receptor. Even more surprisingly, vMIP-II is able to block two distinct types of chemokine receptors, so called CC and CXC receptors. This is the first known molecule able to bind to both types of receptor.

The biological process the virus used to develop vMIP-II is not unlike the chemical process used by Glaxo Wellcome scientists to find new drugs. After lifting a human gene for a chemokine receptor agonist, the virus used genetics to perform a type of biological 'combinatorial chemistry'. This process can be used to produce a family of similar molecules. The virus then tested the related molecules against our own immunological defence mechanisms, making modifications until it found a molecule with the desired properties. In this particular case, the virus was hunting for a molecule that would prevent an inflammatory immune response that might clear the virus.

"The hope is that by understanding how the virus made this antagonist, we will learn lessons which will help us in the design of our own drugs. The virus has given us a substantial lesson in the rules of drug design", said Dr Tim Wells of the Glaxo Wellcome Geneva Institute of Biomedical Research.

vMIP-II is the only known molecule to block all main co-receptors used by HIV to gain entry to cells (CCR5, CCR3, CXCR4 and US28). Full details of the research, carried out in a three way collaboration with the Geneva Glaxo Wellcome group and teams led by Dr Thue Schwartz in Copenhagen and Dr Paul Clapham in London, are reported in the September 12th issue of Science.

The research adds to the growing evidence that chemokine antagonists may lead to novel approaches to HIV therapy either to prevent initial infection or to slow down disease progression in an already infected patient. Importantly, this research shows for the first time that it is possible to block both types of chemokine receptor used by HIV with one molecule. "vMIP-II will help us understand the structural differences between these two types of receptors and may lead to the discovery of a small molecule that would block both receptors," said Dr Wells. HIV uses CCR5 as a co-receptor to gain entry to macrophages during the initial infection and asymptomatic phase of the disease. Later on, HIV mutates allowing it to gain entry to T cells through CXCR4.

Biologically, the virus appears to have optimised vMIP-II to block leukocyte recruitment to the site of Kaposi's sarcoma. HHV-8 is most probably using the novel chemokine to shut off the inflammatory response that would normally be associated with a tumour. This means it may also be a useful tool in diseases such as rheumatoid arthritis or asthma where the human immune system is abnormally activated or even as a means of understanding transplant rejection. It may also lead to useful anti-inflammatory agents for asthma and rheumatoid arthritis.
-end-

For further information contact:

Dr Tim Wells, Geneva Biomedical Research Institute,
Glaxo Wellcome Research and Development SA, 14 chemin des Aulx,
1228 Plan-les-Ouates, Geneva, Switzerland,
Tel: +4122 7069 804/824,
Fax: +41 22 794 6965,
e-mail tncw5312@ggr.co.uk

Philip Connolly,
Group Public Affairs,
Glaxo Wellcome plc,
Glaxo Wellcome House, Berkeley Avenue,
Greenford, Middx, UB6 0NN.
Tel: +44 181 966 8185,
Fax: +44 181 966 8827,
e-mail pgc2355@ggr.co.uk

. Emma Weitkamp,
Hayhurst Conington Cripps, Fry's Yard,
39-40 Bridge Street,
Godalming, Surrey, GU7 1HP.
Tel: +44 1483 414182,
Fax: +44 1483 414157,
e-mail emma@hcc.co.uk

GlaxoSmithKline US

Related HIV Articles from Brightsurf:

BEAT-HIV Delaney collaboratory issues recommendations measuring persistent HIV reservoirs
Spearheaded by Wistar scientists, top worldwide HIV researchers from the BEAT-HIV Martin Delaney Collaboratory to Cure HIV-1 Infection by Combination Immunotherapy (BEAT-HIV Collaboratory) compiled the first comprehensive set of recommendations on how to best measure the size of persistent HIV reservoirs during cure-directed clinical studies.

The Lancet HIV: Study suggests a second patient has been cured of HIV
A study of the second HIV patient to undergo successful stem cell transplantation from donors with a HIV-resistant gene, finds that there was no active viral infection in the patient's blood 30 months after they stopped anti-retroviral therapy, according to a case report published in The Lancet HIV journal and presented at CROI (Conference on Retroviruses and Opportunistic Infections).

Children with HIV score below HIV-negative peers in cognitive, motor function tests
Children who acquired HIV in utero or during birth or breastfeeding did not perform as well as their peers who do not have HIV on tests measuring cognitive ability, motor function and attention, according to a report published online today in Clinical Infectious Diseases.

Efforts to end the HIV epidemic must not ignore people already living with HIV
Efforts to prevent new HIV transmissions in the US must be accompanied by addressing HIV-associated comorbidities to improve the health of people already living with HIV, NIH experts assert in the third of a series of JAMA commentaries.

The Lancet HIV: Severe anti-LGBT legislations associated with lower testing and awareness of HIV in African countries
This first systematic review to investigate HIV testing, treatment and viral suppression in men who have sex with men in Africa finds that among the most recent studies (conducted after 2011) only half of men have been tested for HIV in the past 12 months.

The Lancet HIV: Tenfold increase in number of adolescents on HIV treatment in South Africa since 2010, but many still untreated
A new study of more than 700,000 one to 19-year olds being treated for HIV infection suggests a ten-fold increase in the number of adolescents aged 15 to 19 receiving HIV treatment in South Africa, according to results published in The Lancet HIV journal.

Starting HIV treatment in ERs may be key to ending HIV spread worldwide
In a follow-up study conducted in South Africa, Johns Hopkins Medicine researchers say they have evidence that hospital emergency departments (EDs) worldwide may be key strategic settings for curbing the spread of HIV infections in hard-to-reach populations if the EDs jump-start treatment and case management as well as diagnosis of the disease.

NIH HIV experts prioritize research to achieve sustained ART-free HIV remission
Achieving sustained remission of HIV without life-long antiretroviral therapy (ART) is a top HIV research priority, according to a new commentary in JAMA by experts at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

The Lancet HIV: PrEP implementation is associated with a rapid decline in new HIV infections
Study from Australia is the first to evaluate a population-level roll-out of pre-exposure prophylaxis (PrEP) in men who have sex with men.

Researchers date 'hibernating' HIV strains, advancing BC's leadership in HIV cure research
Researchers have developed a novel way for dating 'hibernating' HIV strains, in an advancement for HIV cure research.

Read More: HIV News and HIV Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.